Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upDavid Planchard, Solange Peters, Matthew D. Hellmann et al.|Annals of Oncology|2018Cited by 2.3k
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialEdward S. Kim, Jean‐Yves Douillard, Alison Armour et al.|The Lancet|2008Cited by 1.2k
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trialMartin Reck, Silvia Novello, R. Kaiser et al.|The Lancet Oncology|2014Cited by 948
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trialMartin Reck, Tony Mok, Makoto Nishio et al.|The Lancet Respiratory Medicine|2019Cited by 937
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upLizza Hendriks, Martin Reck, Keith M. Kerr et al.|Annals of Oncology|2023Cited by 782